Back Back
EA: Gyn Conferences 2023

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies: Independent 2023 Conference/Congress Coverage

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™

Released: December 13, 2023

Expiration: December 12, 2024

Nicoletta Colombo
Nicoletta Colombo, MD, PhD
Linda R. Duska
Linda R. Duska, MD, MPH
Keiichi Fujiwara
Keiichi Fujiwara, MD, PhD
Alexandra Leary
Alexandra Leary, MD, PhD
Domenica Lorusso
Domenica Lorusso, MD, PhD
David Scott Miller
David Scott Miller, MD, FACOG, FACS
Kathleen N Moore
Kathleen N Moore, MD, MS
Ana Oaknin
Ana Oaknin, MD, PhD
Prof Isabelle Ray-Coquard
Prof Isabelle Ray-Coquard, MD, PhD
Brian Slomovitz
Brian Slomovitz, MD, MS, FACOG
CME/CE Information

Activity

Progress
1 2
Course Completed

Introduction

In the year 2023 alone, several clinical advances on new and emerging treatments, biomarkers, and molecular testing modalities were reported across the various annual meetings for gynecologic cancers, including the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), European Society for Medical Oncology (ESMO), and International Gynecologic Cancer Society (IGCS).

This module is a synopsis of seminal clinical trial data, landmark clinical trial updates, and new original research presented for endometrial, cervical, and ovarian cancers at the various global meetings and as highlighted by the experts: David Scott Miller, MD, FACOG, FACS; Linda Duska, MD, MPH; Kathleen Moore, MD, MS; Nicoletta Colombo, MD, PhD; Alexandra Leary, MD, PhD; Domenica Lorusso, MD, PhD; Ana Oaknin, MD, PhD; Isabelle Ray-Coquard, MD, PhD; Brian Slomovitz, MD, MS, FACOG; and Keiichi Fujiwara, MD, PhD.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with gynecologic cancer do you provide care for in a typical month?

Your patient with high-risk, FR𝝰-high, HER2-positive, BRCA mutation–negative, high-grade serous ovarian cancer has evidence of progression (by PET/CT imaging) within 6 months of starting therapy with carboplatin and paclitaxel.

Which of the following FDA-approved treatment options has demonstrated improved survival in this patient population?

Your patient has a history of high-risk serous endometrial cancer. She presents with new lung metastases, and biopsy reveals recurrent endometrial cancer with a P53 mutation, her tumor is HER2 low (inconclusive) and has mismatch repair deficient (dMMR) status by immunohistochemistry testing.

In your current practice, and considering most recent FDA approvals and guideline recommendations, which of the following treatments would be the optimal choice for this patient?

Your patient with recurrent/metastatic cervical cancer experiences disease progression following platinum-based chemotherapy plus pembrolizumab and bevacizumab.

Which of the following treatments would you consider the optimal next therapy for your patient with recurrent/metastatic cervical cancer?

In the phase III DUO-E trial evaluating carboplatin and paclitaxel plus durvalumab followed by durvalumab maintenance with or without olaparib vs carboplatin and paclitaxel alone in newly diagnosed stage III/IV or recurrent endometrial cancer, which of the following populations achieved progression-free survival improvement with durvalumab with olaparib maintenance?

BACK | NEXT